Brii Biosciences shared significant insights into HBsAg rebound profiles post-treatment, demonstrating promising outcomes for hepatitis B patients at the APASL 2026 conference in Istanbul.

Updated APASL guidelines on acute variceal bleeding, responding to recent advances in hemodynamic management, risk stratification, pharmacotherapy, endoscopy techniques, hemostatic devices, and…

Antiviral treatment for HBV lowers the risk for liver cancer and other complications and can prevent transmission.

In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?

WHO has released new Guidelines on prevention, diagnosis and treatment of chronic hepatitis B (HBV) infection at the 2024 Asian Pacific Conference for the Study of Liver Disease (APASL) in Kyoto, Japa...

Sarin, S. K. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol. Int. 13, 353–390 (2019). Sarin, S. K. & Choudhury, A. Acute-on-chronic liver failure: terminology, mechanisms...

The comprehensive, standardized framework provided by the APASL ACLF Beijing Position Paper takes a big step towards improving outcomes globally for critically sick patients with acute-on-chronic…

YouTube video by EASL - Home of Hepatology

Take this survey powered by surveymonkey.com. Create your own surveys for free.

– Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds

APASL 2026 in Istanbul covered 60+ topics across liver disease. Here are the most clinically impactful updates your practice needs.

Ask AI-powered questions about gastroenterology and enhance your academic learning.

高雄醫學大學校長、講座教授余明隆因在C型肝炎、肝癌治療及精準醫療領域重大貢獻，近日榮獲亞太肝臟研究協會「Powell-Sarin成就獎」。高醫大表示，余明隆也是首位獲此獎項的台灣學者。